Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 23:00:00 14/05/2025 +03			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

15/05/25	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/05/25	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Market Cap	29.74M 26.15M 24.34M 22.35M 41.97M 2.85B 42.53M 289M 113M 1.41B 112M 109M 4.87B	P/E 2023	-1.28x	P/E 2024	-0.93x
Enterprise Value	-46.92M -41.25M -38.4M -35.26M -66.21M -4.5B -67.08M -456M -178M -2.22B -176M -172M -7.68B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

15/05/25	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
15/05/25	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
15/05/25	Allakos Inc. Announces Executive Changes	CI
15/05/25	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
15/05/25	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
09/05/25	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
07/05/25	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
02/04/25	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
02/04/25	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
02/04/25	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
12/03/25	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
12/03/25	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
27/01/25	Top Midday Decliners	MT

17/01/24	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
17/01/24	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
17/01/24	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
16/01/24	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
16/01/24	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Stock

Stocks

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Latest news : Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Allakos Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

22/07/22	Lonza-Aktien sinken nach Halbjahreszahlen
05/12/19	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
05/12/19	Des marchés moins cyclothymiques pour finir la semaine ?

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/15/25 A	Steven James	Issuer sale	Director	332,932	0.3726%
5/15/25 A	Robert Andreatta	Issuer sale	Director	296,352	0.3317%
5/15/25 A	Robert Alexander	Issuer sale	Chief Executive Officer	5,280,211	5.9100%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	-.--%	-93.06%	29.74M
LONZA GROUP AG	+2.08%	-1.48%	-1.34%	+14.07%	46.86B
REVOLUTION MEDICINES, INC.	-0.61%	+1.03%	+396.16%	+643.07%	40.23B
BEONE MEDICINES AG	0.00%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+2.48%	+3.37%	+7.05%	-8.08%	34.72B
CELLTRION, INC.	+0.62%	+1.65%	+5.41%	+43.89%	27.89B
MEDPACE HOLDINGS, INC.	-2.00%	+9.60%	+31.71%	+129.76%	16.79B
ASCENDIS PHARMA A/S	-0.17%	-2.90%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.78%	-4.78%	-2.68%	+9.96%	13.12B
ICON PUBLIC LIMITED COMPANY	+1.82%	-0.72%	-9.75%	-33.31%	12.7B
Average	+0.45%	+0.87%	+48.71%	+85.23%	24.53B
Weighted average by Cap.	+0.62%	+1.05%	+74.69%	+138.07%

	2023	2024
Net sales	-	-
Net income	-186M -163M -152M -140M -262M -17.81B -266M -1.81B -705M -8.79B -697M -682M -30.39B	-116M -102M -94.78M -87.04M -163M -11.11B -166M -1.13B -440M -5.48B -435M -425M -18.96B
Net Debt	-129M -114M -106M -97.19M -183M -12.4B -185M -1.26B -491M -6.12B -485M -475M -21.17B	-76.66M -67.39M -62.73M -57.61M -108M -7.35B -110M -746M -291M -3.63B -288M -282M -12.55B

3 years	0.22	5.64
5 years	0.22	112.87
10 years	0.22	157.98